Il33 antibodies and methods of using the same

Abstract

The present invention provides isolated IL-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against IL-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.

What is claimed is: 
     
         1 . A method for treating a subject with an inflammatory condition comprising administering to the subject an effective amount of an antibody or antigen-binding fragment thereof which specifically binds to IL-33. 
     
     
         2 . The method of  claim 1 , wherein the antibody or antigen-binding fragment thereof inhibits IL-33 driven cytokine production. 
     
     
         3 . The method of  claim 1 , wherein the antibody or antigen-binding fragment thereof inhibits RAGE mediated effects. 
     
     
         4 . The method of  claim 1 , wherein the inflammatory condition is an allergic disorder. 
     
     
         5 . The method of  claim 1 , wherein the inflammatory condition is asthma or COPD. 
     
     
         6 . The method of  claim 1 , wherein the inflammatory condition is in the airway of the subject. 
     
     
         7 . The method of  claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a VHCDR1 having the sequence of SEQ ID NO: 183, a VHCDR2 having the sequence of SEQ ID NO: 184, a VHCDR3 having the sequence of SEQ ID NO: 185, a VLCDR1 having the sequence of SEQ ID NO: 188, a VLCDR2 having the sequence of SEQ ID NO: 189, and a VLCDR3 having the sequence of SEQ ID NO: 190. 
     
     
         8 . The method of  claim 7 , wherein the VH and VL of the antibody or antigen-binding fragment thereof comprise amino acid sequences at least 95%, 90%, or 85% identical to SEQ ID NO: 182 and SEQ ID NO: 187, respectively. 
     
     
         9 . The method of  claim 8 , wherein the VH has the sequence of SEQ ID NO: 182 and the VL has the sequence of SEQ ID NO: 187. 
     
     
         10 . The method of  claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a VHCDR1 having the sequence of SEQ ID NO: 543, a VHCDR2 having the sequence of SEQ ID NO: 544, a VHCDR3 having the sequence of SEQ ID NO: 545, a VLCDR1 having the sequence of SEQ ID NO: 548, a VLCDR2 having the sequence of SEQ ID NO: 549, and a VLCDR3 having the sequence of SEQ ID NO: 550. 
     
     
         11 . The method of  claim 10 , wherein the VH and VL of the antibody or antigen-binding fragment thereof comprise amino acid sequences at least 95%, 90%, or 85% identical to SEQ ID NO: 542 and SEQ ID NO: 547, respectively. 
     
     
         12 . The method of  claim 11 , wherein the VH has the sequence of SEQ ID NO: 542 and the VL has the sequence of SEQ ID NO: 547. 
     
     
         13 . The method of  claim 10 , wherein the VH and VL of the antibody or antigen-binding fragment thereof comprise amino acid sequences at least 95%, 90%, or 85% identical to SEQ ID NO: 616 and SEQ ID NO: 618, respectively. 
     
     
         14 . The method of  claim 13 , wherein the VH has the sequence of SEQ ID NO: 616 and the VL has the sequence of SEQ ID NO: 618. 
     
     
         15 . The method of  claim 1 , wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of a human antibody, a chimeric antibody, and a humanized antibody. 
     
     
         16 . The method of  claim 1 , wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of a naturally-occurring antibody, an scFv fragment, an Fab fragment, an F(ab′)2 fragment, a minibody, a diabody, a triabody, a tetrabody, and a single chain antibody. 
     
     
         17 . The method of  claim 1 , wherein the antibody or antigen-binding fragment thereof is a monoclonal antibody.